Research on the biology of tumor cells. Covers tumor spread, cell-particle diagnostics, new anti-tumor molecules, and cancer-killing immune cells.
Neuroblastoma tumour cells adapt to mimic embryonic cells, making them resistant to chemotherapy. This understanding can lead to targeted treatments that better reach the entire tumour and avoid resistance development.
Researchers have discovered that targeting a specific mutation in fibrolamellar tumors can reduce tumor growth in mice, offering a promising approach to treating this nearly incurable cancer. The findings highlight the potential for novel therapies against an intractable disease.
Researchers at IRB Barcelona have identified the tiny fraction of tumour cells that remain hidden after surgery, leading to metastatic recurrence. These 'High Relapse Cells' can be eliminated through genetic techniques, preventing metastases and opening the possibility for new therapeutic strategies.
Researchers have discovered two novel drugs that can block the growth and shrink the size of schwannoma tumors, a type of nerve sheath tumor found in the nervous system. The treatment works by inhibiting the Hippo signaling pathway, which is dysregulated in multiple types of cancer.
Researchers used DNA barcoding to track breast cancer cells over time, finding that some cells can suppress killer T-cells and reduce MHC1 expression to evade the immune system. This study suggests epigenetic mechanisms may play a role in cancer cell adaptation and provides potential targets for therapies.
Researchers at VCU Massey Cancer Center have found strong evidence for testing a novel drug in liver cancer treatment. MDA-9 inhibition may be an effective approach for hepatocellular carcinoma (HCC), with potential synergies with other therapeutics.
A new method of modifying our immune system has been demonstrated in a study published in Advanced Science, which could help treat skin cancer.
A new study suggests that chlorhexidine gluconate (CHG) is the most effective irrigation solution for killing bone tumor cells after surgery. CHG shows highest cytotoxicity against chondrosarcoma and giant cell tumors, potentially making it a useful chemical adjuvant during intralesional curettage.
Researchers at the University of Seville have discovered a method to attack cancer cells using an origin-of-life molecule. The study found that inhibiting RNA production boosts the utility of radiation therapy in cancer cells, offering a promising approach to treating various types of cancer.
Filopodia contribute to building a barrier surrounding breast tumours, blocking their escape. Cancer cells lacking Myosin-10 cannot maintain this barrier, making it easier for them to spread.
Researchers at UNIGE have discovered a way to overcome resistance to chemotherapy in colorectal cancer, using an optimized combination of tyrosine kinase inhibitors. This breakthrough opens up new avenues for developing targeted therapies that can effectively treat patients with low five-year survival rates.
Researchers at Mount Sinai's Tisch Cancer Institute have discovered a new gene, PDZK1IP1, essential to colon cancer growth. The study found that surrounding inflammation activates the super enhancer, promoting tumor cell survival and growth.
A gene signature of four specific genes (SAA1, SAA2, APOL1, and MET) predicts the risk of tumour spreading and survival in kidney cancer patients. The study identified a link between the microenvironment and immune system inhibition.
Recruitment of tumor-fighting macrophages depends on testosterone. Administering testosterone to females increases macrophage ability to eradicate tumor cells.
Researchers developed a low-cost, simple imaging system using tumor-targeting fluorescent molecules to determine tumor depth. The portable system provides quantitative information about the depth of tumor cells in the body, helping surgeons remove healthy tissue around tumors for better outcomes.
A team of 15 doctoral researchers is investigating targeted cancer treatments by developing special molecules that stimulate the immune system to destroy tumor cells. These minimally invasive anti-cancer drugs attach a substance that damages tumor tissue to a transporter molecule, recognizing and delivering it to cancerous cells.
A study published in Science reveals that tumor cells with a specific mutation release a chemical metabolite that weakens nearby immune cells, rendering them less capable of killing cancer cells. The findings highlight the critical role of the tumor microenvironment in cancer growth and provide insights into developing targeted therapi...
Researchers have developed a new approach to test the efficacy of multiple anticancer drug combinations simultaneously, rapidly, and accurately. Combi-seq overcomes limitations of conventional technologies by using microfluidics to carry out large-scale experiments with small sample volumes.
Researchers at the University of Helsinki have identified target genes of the MYC oncogene responsible for its growth-promoting effects. By modifying these genomic binding sites, they slowed down cell growth. This finding has significant implications for developing new cancer treatments.
Researchers discovered a type of triple-negative breast cancer cell that can trigger dormancy, evading therapies and allowing for efficient survival in distant organs. This finding highlights the need for more selective therapeutic strategies targeting both dividing and invasive dormant cells.
Research reveals that tumor cells form temporary structures to avoid destruction by the immune system. The findings suggest that timed inhibition of relevant signaling pathways is necessary alongside immunotherapy to prevent tumor resistance.
Researchers at University of California - San Francisco have developed a new therapy that overcomes cancer cell barriers and marks them for destruction by the immune system. By pulling mutated KRAS protein to the surface, the drug acts as an “eat me” flag, allowing immunotherapy to eliminate all cells bearing this flag.
A new study provides valuable insights into the roles of B cells and plasma cells in early-stage lung cancer biology, highlighting their influence on tumor development and treatment outcomes. The research also reveals environmental factors and molecular features that contribute to the landscape of infiltrating immune cells.
Bladder cancer researchers discovered a subset of CD8 T cells that adapts to tumor evasion strategies, offering a strategy to reduce tumor cells' ability to fight them off. The study also identified potential ways to make immunotherapy more effective against this deadly cancer by targeting the HLA-E/NKG2A axis.
Researchers at Tel Aviv University develop a groundbreaking method to eradicate glioblastoma brain tumors by targeting astrocytes and starving them of energy. The study found that in the absence of these brain cells, tumor cells die and are eliminated, offering a promising basis for developing effective medications.
Researchers have identified fascin as a key player in promoting cancer development, with the protein controlling cell movement and invasion. Forcing fascin into the nucleus of cancer cells could prevent their growth and movement.
Researchers at LSU Health New Orleans have identified a critical immunosuppressive pathway and developed an experimental inhibitor to protect T-cells from weakening. The CBL-B inhibitors show great potential in enhancing the efficacy of cancer immunotherapy, making patients' T-cells more effective in killing cancer cells.
A University of Houston engineer has developed technology to determine which patients are likely to respond to CAR T-cell therapy for lymphoma, saving time and increasing success rates. The TIMING method analyzes interactions between T cells and tumor cells, identifying a key ligand molecule that predicts patient response.
Scientists have developed a smart contact lens that can capture and detect exosomes, nanometer-sized vesicles found in bodily secretions, which hold promise for cancer diagnostics. The lens was designed to bind to antibodies capturing exosomes found in tears, offering a potential platform for non-invasive cancer screening.
Researchers found that Merkel cell carcinoma (MCC) Glypican-3 (GPC3) is expressed in nearly 70% of MCC tumors and up to 90% of MCPyV-negative cases. GPC3 expression is associated with worse prognosis, including increased risk of death from MCC. This makes GPC3 a promising target for chimeric antigen receptor T cell therapy.
Researchers have identified key molecular differences between cancer cells that cling to initial tumors and those that spread to distant sites. The study found unique properties in cells that gain migratory ability and survival advantages, leading to the development of new treatment targets.
Researchers at the University of Pittsburgh have discovered that even terminally exhausted T cells retain some capacity to function again. They identified approaches to overcome exhaustion by targeting co-stimulation pathways and reprogramming T cells to be resistant to hypoxia, a common tumor microenvironmental signal.
Researchers at Dartmouth Cancer Center developed a new approach for detecting and quantifying tumor heterogeneity in breast cancer. High levels of heterogeneity are linked to poor patient outcomes, while specific proteins regulate its extent. The study aims to utilize this approach in therapeutic decision-making.
A new study by Tokyo University of Science researchers reveals that dendritic cell immunoreceptor (DCIR) plays a crucial role in the development of colorectal tumors. Blocking DCIR may prevent ulcerative colitis and colon cancer, offering a potential therapeutic target for treating these diseases.
Researchers discovered that liver cancer cells modify their metabolism to leave them susceptible to disruptions in arginine supply, a key molecule. A three-pronged approach targeting tumor metabolism, blocking survival-promoting responses, and starving tumors of arginine can induce senescence, making cancer cells killable.
Leukemia cells exploit metabolic pathways to evade programmed cell death, but researchers identified a weak spot in acute lymphoblastic leukemia that can be targeted with experimental drugs. Inhibiting glutathione metabolism induces ferroptosis, leading to the death of malignant lymphocytes.
Researchers at TIBI developed a minimally invasive method for targeted delivery of immunotherapeutic treatments, resulting in slower tumor growth and higher activation of T-cells. The injectable gelatin biomaterial containing silicate nanoplatelets showed sustained drug release and controlled ICI delivery.
Researchers created a novel tumor organoid system to examine the impact of bacterial metabolites on immune checkpoint blockage, a promising cancer treatment. The system showed that certain bacterial-released factors improved immune cell viability and increased treatment efficacy.
Osaka University researchers identified medullary thymic epithelial cells (mTECs) expressing neuromuscular molecules in myasthenia gravis-thymoma samples. These findings suggest a new connection between the two diseases and may lead to novel therapeutic methods.
A team of researchers has discovered that malignant tumors accumulate lipid delivery molecules called LDL and attract immune suppressor cells called neutrophils, leading to tumor progression. The study also shows that targeting the LOX-1/oxidized LDL axis may be a promising strategy for treating both cancer and cardiovascular disease.
Researchers at Max Delbrück Center for Molecular Medicine found that silencing the EBAG9 gene in CAR T cells increases their effectiveness and reduces side effects. This breakthrough could lead to a new therapy approach for blood cancer patients.
Researchers at Cold Spring Harbor Laboratory have developed a rapid organoid screening test that can predict response to neoadjuvant chemotherapy in pancreatic cancer patients. This test may help optimize personalized treatment plans and improve patient outcomes.
Scientists at the University of Nottingham have developed a new dressing that can prevent the recurrence of melanoma by killing cancer cells while promoting healthy cell growth. The dressing is made with graphene oxide, elastin, and ethanol, and requires only 15 seconds of Near Infrared light every 48 hours to be effective.
Researchers have uncovered how tissue stiffness determines cell positioning and regulates cell migration in various types of cancer, including brain tumors and breast cancer. The study provides new possibilities for stopping and directing cancer cell migration.
A new study by University of Cambridge researchers found that male dogs are four to five times more likely than female dogs to be infected with the oro-nasal form of Canine Transmissible Venereal Tumour. This unusual cancer is infectious and can spread between dogs through contact, commonly affecting genitals but also the nose and mouth.
Researchers have found that tumor cells co-exist with normal tissue in a complex, heterogeneous mixture, leading to unexpected effects on therapeutic resistance. The study suggests that understanding these ecological interactions could lead to novel treatment strategies and improved patient outcomes.
Research from RCSI University of Medicine and Health Sciences found a link between high von Willebrand Factor levels and poorer breast cancer outcomes. High levels in the bloodstream can increase the risk of life-threatening blood clots and cancer spread in patients.
Researchers found that tumour stem cells with Mex3a protein activity remain in a latent state, conferring resistance to chemotherapy. After treatment, these cells are reactivated, leading to cancer relapse. Removing the Mex3a gene makes colorectal cancer cells highly sensitive to chemotherapy.
Researchers will develop and test new beacon molecules and imaging equipment to improve the detection and removal of non-small-cell lung cancers, aiming to reduce unnecessary tissue removal. The goal is to enhance surgical outcomes and improve patient care.
A study by Michigan Medicine researchers has identified oncostreams, highly active cells connected to brain tumor growth and invasion. The team found that eliminating Collagen 1 production from tumor cells reduces tumor aggressive behavior. This discovery could lead to novel therapeutic targets for treating lethal brain tumors.
A new study from Karolinska Institutet has identified a key mechanism behind treatment resistance in a deadly form of kidney cancer. By increasing mitochondrial content in cancer cells, researchers found that these cells became susceptible to the cancer drug sorafenib. This breakthrough offers hope for more targeted cancer treatments.
Researchers at the Netherlands Cancer Institute discovered that prostate cancer cells hijack the circadian rhythm to become resistant to hormone therapy. The study found that proteins regulating the circadian clock play a crucial role in tumor cell survival, offering a potential target for new treatment strategies.
Scientists have created new fluorescent chemical compounds for photodynamic therapy of cancerous tumors, which can stain affected tissues and destroy tumor cells without harm to healthy ones. The compound containing pyrene shows the highest fluorescent and anticancer activity.
Researchers have discovered a protein produced by soft-tissue sarcoma tumors that changes the biology of surrounding immune cells, promoting tumor growth. The study could lead to improved treatments for this rare and aggressive cancer type.
Researchers at Kyoto University identified the mechanism behind active inflammation and immunosuppression in tumor microenvironments. EP2/EP4 inhibitors suppress tumor growth by allowing regulatory T cells to infiltrate and activate within tumors, benefiting patients with certain cancers.
Researchers have developed a molecule that uses nanotechnology, chemotherapy and a monoclonal antibody to target glioblastoma multiforme, the most aggressive type of brain cancer. The treatment showed promise in isolated cells and animal models, with significant reductions in tumor volume and no increased toxicity.
Researchers developed a mathematical technique to measure total tumor-specific mRNA levels from bulk tumor sequencing data, associating higher mRNA levels with reduced patient survival. The study suggests this approach could serve as a prognostic biomarker for various cancers, guiding treatment selection.
A new machine learning algorithm called 'ikarus' has found a gene signature characteristic of tumors, distinguishing between healthy and tumor cells in various types of cancer. The algorithm was trained on single-cell sequencing data sets and demonstrated an extraordinarily high success rate in distinguishing between different cell types.
Researchers have reported encouraging early-stage data for the Phase 1 clinical trial of INB-200, a gamma-delta T cell-based immunotherapy. All patients enrolled in the trial have exceeded their expected progression-free survival, with two patients exceeding overall survival as well. The treatment shows promising activity against gliob...
Scientists at Max Delbrück Center identify EBAG9 gene as key inhibitor of T cell function against tumors, releasing the brake and boosting immune response. The discovery aims to develop CAR T cells without EBAG9 for more effective leukemia treatments.